Situaciones clínicas y tratamiento del Cáncer de Pulmón EGFR mutado

9 / 49

Enrollment period:
Sep. 2012~May. 2015
All efficacy analyses were conducted on the ITT population (all randomized patients).
ITT, intend to treat, Tx, treatment, PD, disease progression * No study medication received
Enrolled n=102
Abstract ID: 8717
• No study medication received n=1
• Major Protocol Violation n=4
– No R0 resection n=3
– Critical assessment deficiency n=1
• No study medication received n=8
• Major Protocol Violation n=11
– No R0 resection n=5
– Critical assessment deficiency n=3
– Prior anti-neoplastic Tx n=1
– Metastatic before study Tx * n=1
– Other anti-neoplastic Tx before PD n=1
Randomized to Erlotinib n=51 Randomized to Chemotherapy n=51
Available for primary analysis
• ITT analysis population n=51
• Safety analysis population n=50
• Per-protocol population n=46
Available for primary analysis
• ITT analysis population n=51
• Safety analysis population n=43
• Per-protocol population n=33
Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA EGFRMutant NSCLC Patients (EVAN, NCT01683175)